1-(4-cyanobenzoyl)piperazine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-cyanobenzoyl)piperazine
• 英文别名: 4-(piperazine-1-carbonyl)benzonitrile
• 化学式: C₁₂H₁₃N₃O
• mdl: MFCD08443156
• 分子量: 215.255
• InChiKey: DIAXYBAIVPIEGQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  56.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-[(4-oxo-3H-phthalazin-1-yl)methyl]thiophene-3-carboxylic acid 、 1-(4-cyanobenzoyl)piperazine 在 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 水 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 49.0h， 生成 4-[4-[5-[(4-oxo-3H-phthalazin-1-yl)methyl]thiophene-3-carbonyl]piperazine-1-carbonyl]benzonitrile
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors

  摘要：

  We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors. Preliminary biological evaluation indicated that most compounds possessed inhibitory potencies comparable to, or higher than AZD-2281. Among these compounds, 18q appeared to be the most notable one, which displayed an 8-fold improvement in enzymatic activity compared to AZD-2281. These efforts lay the foundation for our further investigation.

  DOI：

  10.1016/j.bmcl.2014.07.001
• 作为产物：
  描述：

  4-(4-cyano-benzoyl)-piperazine-1-carboxylic acid tert-butyl ester 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-(4-cyanobenzoyl)piperazine
  参考文献：
  名称：

  Synthesis and biological evaluation of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors

  摘要：

  We have developed a series of substituted 4-(thiophen-2-ylmethyl)-2H-phthalazin-1-ones as potent PARP-1 inhibitors. Preliminary biological evaluation indicated that most compounds possessed inhibitory potencies comparable to, or higher than AZD-2281. Among these compounds, 18q appeared to be the most notable one, which displayed an 8-fold improvement in enzymatic activity compared to AZD-2281. These efforts lay the foundation for our further investigation.

  DOI：

  10.1016/j.bmcl.2014.07.001

文献信息

• Aminolysis of S-4-Nitrophenyl X-Substituted Thiobenzoates: Effect of Nonleaving-Group Substituents on Reactivity and Mechanism
  作者：Li-Ra Im、Sang-Eun Jeon、Ik-Hwan Um

  DOI：10.5012/bkcs.2011.32.4.1153

  日期：2011.4.20

  A kinetic study is reported for aminolysis of S-4-nitrophenyl X-substituted thiobenzoates 3a-g in 80 mol % $H_2O$/20 mol % DMSO at $25.0\pm}0.1^\circ}C$. Thiol esters 3a-g are 7.8-47.6 fold more reactive than the corresponding oxygen esters (i.e., 4-nitrophenyl X-substituted benzoates 1a-g). Such reactivity order appears to be in accordance with the expectation that 4-nitrothiophenoxide in 3a-g is a better nucleofuge than 4-nitrophenoxide in 1a-g since the former is 2.64 pKa units less basic than the latter. Hammett plot for the reactions of 3a-g exhibit poor correlation coefficients ($R^2$ = 0.977-0.986) with negative deviation by substrates possessing an electrondonating group (EDG), while the Yukawa-Tsuno plots result in excellent linear correlation ($R^2$ = 0.995-0.997) with $\rho}$ = 0.93-1.23 and r = 0.57-0.67, indicating that the negative deviation shown by substrates possessing an EDG is caused by ground-state stabilization through resonance interactions but not due to a change in ratedetermining step upon changing the nonleaving-group substituent X. The $\rho}$ value increases as the incoming amine becomes more basic and more reactive, indicating that the RSP is not operative in the current reactions.

  报道了一项关于S-4-硝基苯基X取代硫代苯甲酸酯3a-g在80摩尔%水/20摩尔% DMSO中于25.0±0.1°C进行的氨基水解的动力学研究。硫酯3a-g的反应性是相应的氧酯（即4-硝基苯基X取代苯甲酸酯1a-g）的7.8-47.6倍。这种反应性顺序似乎符合预期，因为3a-g中的4-硝基硫苯氧负离子比1a-g中的4-硝基苯氧负离子更容易转移，前者的碱性比后者低2.64个pKa单位。3a-g的反应的Hammett图显示，具有电子给体基团（EDG）的底物的相关系数较差（R² = 0.977-0.986），且呈负偏差，而Yukawa-Tsuno图则显示出良好的线性相关性（R² = 0.995-0.997），并且ρ = 0.93-1.23，r = 0.57-0.67，这表明具有EDG的底表现出的负偏差是由共振相互作用造成的基态稳定化，而不是由于改变非离去基团取代基X时速率决定步骤的变化。随着入体胺的碱性和反应性增强，ρ值增加，表明在当前反应中，RSP机制并未起作用。
• Exploration of 6,7-dimethoxyquinazoline derivatives as dual acting α₁- and AT₁-receptor antagonists: synthesis, evaluation, pharmacophore & 3D-QSAR modeling and receptor docking studies
  作者：Neetesh Agrawal、Jatin Machhi、Virendra Rathwa、Ashish M. Kanhed、Sagar Patel、Prashant Murumkar、Hardik Gandhi、Mange Ram Yadav

  DOI：10.1039/c6ra00589f

  日期：——

  ne scaffold was further explored to provide dual acting α1- and AT1-receptor antagonists by synthesizing a series of derivatives and biologically evaluating the newly synthesized compounds. Based on the biological data of the current compounds and the earlier reported compounds, pharmacophore models were developed for α1- and AT1-receptor antagonist activities. Subsequently, 3D-QSAR models were also

  6,7-二甲氧基支架进一步探索了α提供双重作用的1 -和AT 1通过合成一系列衍生物和生物学评价新合成的化合物受体拮抗剂。根据目前的化合物的生物数据和此前报道的化合物，药效模型，用于开发α 1 -和AT 1-受体拮抗剂的活性。随后，还导出了两种受体的拮抗作用的3D-QSAR模型。使用各种统计参数对开发的3D-QSAR模型进行了验证，并且使用特拉唑嗪和哌唑嗪作为外部化合物进一步验证了两种开发模型。对接研究证实受体-配体稳定平衡-双活性拮抗剂（的相互作用110在两个α的活性位点）1 -以及AT 1 -受体，这些都是由同源性建模所获得的结构。两个（42和110从新合成的衍生物的化合物的）所提供的最高效力（p阿2为α 1=分别为9.45和8.77，以及AT 1分别为8.36和8.60），并且两个受体的平衡调节。既发现本化合物是特拉唑嗪略小有力作为α 1 -拮抗剂和等效氯沙坦如AT 1 -拮抗剂在体内动物模型。
• Effect of Acyl Substituents on the Reaction Mechanism for Aminolyses of 4-Nitrophenyl X-Substituted Benzoates
  作者：Ik-Hwan Um、Ji-Sook Min、Jung-Ae Ahn、Hyun-Joo Hahn

  DOI：10.1021/jo000482x

  日期：2000.9.1

  due to a change in the rate-determining step upon changing the acyl substituent X, but due to resonance demand of the pi-electron donor substituent on the acyl moiety. The magnitude of the rho(X) and beta(nuc) values increases with increasing the basicity of amines and with increasing the electron-withdrawing ability of the acyl substituent X, respectively, while that of the r values decreases with increasing

  已在25.0摄氏度下用分光光度法测量了4-硝基苯基X-取代的苯甲酸酯与一系列脂环族仲胺在含有20 mol％二甲基亚砜的H（2）O中的反应的二级速率常数（k（N））。 k（N）值的大小随胺的碱度增加和酰基取代基X的吸电子能力增加而增加。获得的Hammett图不是线性的，而是随着酰基取代基X变成电子而出现断裂或曲率。对于所研究的所有胺，均要提取，而对于所有所研究的底物，布朗斯台德型图与大的β（nuc）值呈线性关系。非线性哈米特图表明，在改变酰基取代基X时，速率决定步骤会发生变化，而线性布朗斯台德图表明速率确定步骤在胺碱度改变时不会改变。获得的Yukawa-Tsuno图也具有正rho（X）和大r值的线性关系，这表明非线性Hammett图不是由于改变酰基取代基X时速率决定步骤的变化，而是由于共振需求酰基部分上的π电子供体取代基的“α”。rho（X）和beta（nuc）值的幅度分别随胺的碱度增加和酰
• [EN] CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS<br/>[FR] COMPOSES D'ACIDE CARBAMIQUE COMPRENANT UN CHAINON DE PIPERAZINE TELS QUE LES INHIBITEURS HDAC
  申请人：PROLIFIX LTD

  公开号：WO2003082288A1

  公开（公告）日：2003-10-09

  This invention pertains to certain carbamic acid compounds which inhibit HDAC (histone deacetylase) activity of the following formula:[Insert formula]wherein: Cy is independently a cyclyl group; Q1 is independently a covalent bond or cyclyl leader group; the piperazin-1,4-diyl group is optionally substituted; J1 is independently a covalent bond or -C(=O)- ; J2 is independently -C(=O)- or -S(=O)2- ; Q2 is independently an acid leader group; wherein: Cy is independently: C3-20carbocyclyl, C3-20heterocyclyl, or C5-20aryl; and is optionally substituted; Q1 is independently: a covalent bond; C1-7alkylene; or C1-7alkylene-X-C1-7alkylene, -X-C1-7alkylene, or C1-7alkylene-X-, wherein X is -O- or -S-; and is optionally substituted; Q2 is independently: C4-8alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or: Q2 is independently: C5-20arylene; C5-20arylene-C1-7alkylene; C1-7alkylene-C5-20arylene; or, C1-7alkylene-C5-20arylene-C1-7alkylene; and is optionally substituted; and has a backbone length of at least 4 atoms; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit HDAC, and in the treatment of conditions mediated by HDAC, cancer, proliferative conditions, psoriasis, etc.

  本发明涉及一些碳酰胺化合物，其抑制以下式的HDAC（组蛋白去乙酰化酶）活性：[插入式]其中：Cy独立地是环烷基团；Q1独立地是共价键或环烷基团；哌嗪-1,4-二基基团可选地被取代；J1独立地是共价键或-C（=O）-；J2独立地是-C（=O）-或-S（=O）2-；Q2独立地是酸基团；其中：Cy独立地是C3-20碳环烷基、C3-20杂环烷基或C5-20芳基；并可选地被取代；Q1独立地是：共价键；C1-7烷基；或C1-7烷基-X-C1-7烷基、-X-C1-7烷基或C1-7烷基-X-，其中X是-O-或-S-；并可选地被取代；Q2独立地是：C4-8烷基；并可选地被取代；并且具有至少4个原子的骨架长度；或：Q2独立地是：C5-20芳基；C5-20芳基-C1-7烷基；C1-7烷基-C5-20芳基；或C1-7烷基-C5-20芳基-C1-7烷基；并可选地被取代；并且具有至少4个原子的骨架长度；或其药学上可接受的盐、溶剂化合物、酰胺、酯、醚、化学保护形式或前药。本发明还涉及包含这种化合物的制药组合物，以及这种化合物和组合物的使用，无论是体外还是体内，用于抑制HDAC，并用于治疗由HDAC介导的疾病，如癌症、增殖性疾病、牛皮癣等。
• [EN] N-BENZENESULPHONYL-L-PROLINE DERIVATIVES AS BRADYKININ B2 AGONISTS<br/>[FR] DERIVES DE N-BENZENESULFONYL-L-PROLINE EN TANT QU'AGONISTES DE LA BRADYKININE B2
  申请人：FOURNIER INDUSTRIE ET SANTE

  公开号：WO1998003503A1

  公开（公告）日：1998-01-29

  (EN) Compounds selected from the group which consists of the compounds of formula (I), wherein each of X1 and X2, which are the same or different, is halogen or a C1-3 alkoxy group, R1 is H, CF3 or a C1-3 alkyl group, R2 is a hydrogen atom or an OH group, A is group (a), (b) or (c), B is a single bond, -CO-, -CO-CH2-, -CO-CH2-O-, -CO-CH=CH or -SO2-, m is 2 or 3, n is 0, 1, 2 or 3, R3 is a hydrogen atom or a methyl group, and W is CH or N, the amidine group C(=NR2)NH2 being in the 2, 3 or 4 position on the aromatic ring, and addition salts thereof, are disclosed. A method for preparing said compounds, and the therapeutical use thereof, particularly for treating diseases in which bradykinin is involved, are also disclosed.(FR) La présente invention concerne des composés choisis parmi l'ensemble constitué par (i) les composés de formule (I) dans laquelle: X1 et X2 représentent chacun indépendamment un halogène ou un groupe alkoxy en C1-C3, R1 représente H, CF3 ou un groupe alkyle en C1-C3, R2 représente un atome d'hydrogène ou un groupe OH, A représente un groupe (a), (b) ou (c); B représente une liaison simple, -CO-, -CO-CH2-, -CO-CH2-O-, -CO-CH=CH ou -SO2-, m représente 2 ou 3, n représente 0, 1, 2 ou 3, R3 représente un atome d'hydrogène ou un groupe méthyle, W représente CH ou N, le groupe amidine C(=NR2)NH2 étant en position 2, 3 ou 4 sur le noyau aromatique, et (ii) leurs sels d'addition. Elle concerne également leur procédé de préparation et leur utilisation en thérapeutique, notamment vis-à-vis des pathologies mettant en cause la bradykinine.

  该组化合物选自如下公式(I)的化合物组，其中X1和X2分别表示卤素或C1-3烷氧基，R1表示氢、CF3或C1-3烷基，R2表示氢原子或OH基团，A表示(a)、(b)或(c)基团，B表示单键、-CO-、-CO-CH2-、-CO-CH2-O-、-CO-CH=CH或-SO2-，m为2或3，n为0、1、2或3，R3表示氢原子或甲基基团，W表示CH或N，在芳香环上的酰胺基团C(=NR2)NH2位于2、3或4位置，以及它们的加成盐。还公开了制备该化合物的方法以及它们的治疗用途，特别是用于治疗与缓激肽有关的疾病。